. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Cancer Prev Res (Phila). 2011 Jun 16;4(11):1808–1815. doi: 10.1158/1940-6207.CAPR-11-0113

Table 3. Relative risk (RR) of colon and rectal cancer according to statin use.

Tumor site	Nonusers	Current use
Colon and Rectum ^†
No. of cases	1446	234
Age-adjusted RR	1.00	0.90 (0.78 to 1.04)
Multivariate-adjusted RR^*	1.00	0.97 (0.84 to 1.12)
	Nonuser	Current use

Colon
No. of cases	1083	199
Age-adjusted RR	1.00	1.02 (0.88 to 1.20)
Multivariate-adjusted RR^*	1.00	1.10 (0.94 to 1.29)^‡
Rectum
No. of cases	363	35
Age-adjusted RR	1.00	0.54 (0.38 to 0.77)
Multivariate-adjusted RR^*	1.00	0.59 (0.41 to 0.84)^‡

Adjusted for age, calendar year, study, pack-years of smoking before age 30 (never smoker, 1-4 pack-years, 5-10 pack-years, and ≥ 11 pack-years of smoking), aspirin dose (never, past, current use 1-2, 3-5, 6-14, ≥15 tablets/wk), height (continuous), BMI (<23, 23-<25, 25-<28, 28-<30, ≥30 kg/m² in the NHS; <23, 23-<25, 25-<30, 30-<35, ≥35kg/m² in the HPFS), family history of colorectal cancer in parents and siblings (yes, no), history of endoscopy (yes, no), red meat intake (quintiles), alcohol intake (never, 0.1-9.9 g/d, 10-14.9 g/d, 15-29.9 g/d, ≥30 g/d), and total energy intake (continuous)

^†

Includes cases whose cases were confirmed as colon or rectal cancer.

^‡

P for heterogeneity for colon vs. rectum <0.001